Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Allergy: early-phase trial registry
3 of 16 indexed Allergy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,060 of 28,707 conditions by registered trial count.
16 US clinical trials · 3 currently recruiting · #1,060 of 28,707 conditions by registered trial count
Allergy: 16 US clinical trials tracked, 3 recruiting.
Allergy is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 3 of these trials.
Enrollment posture brief
Registry condition allergy
OPEN 3 | RECR 19% | LATE 2 | EARLY 6 | RANK #1060 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Bacterial Vaginosis (19% recruiting · 16 trials)
Allergy lists 3 open slots (19% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Allergy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Allergy is recruiting below its size-band peers.
3 of 16 indexed trials (18.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Allergy research.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 3 of 16 trials (18.8%). 13 distinct sponsors appear on at least one study for this condition label.
-
Typical Allergy enrolment sits around 100 participants.
Median target enrolment is 100 among the 16 trials that report a genuine target (sentinel values excluded). 8 of those (50%) plan for fewer than 100 participants.
-
Allergy splits between interventional and observational designs.
9 interventional and 7 observational studies make up this index (56.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
16 total, page 1 of 1
Understanding Allergies and Sensitizations in Healthy and Allergic Individuals
Stanford University
NCT04828603
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
DBV Technologies
NCT07003919
The Nonirritating Concentrations of Midazolam, Ketamine, and Ondansetron
Mayo Clinic
NCT07103720
Childhood Allergy and the Neonatal Environment
University of Wisconsin, Madison
NCT04215783
Urban Environmental Factors and Childhood Asthma
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00114881
Vitamin D, Steroids, and Asthma in African American Youth
Robert J. Freishtat
NCT01647399
Neuromuscular Blocking Agents Utilized During Perioperative Hypersensitivity Evaluation
Mayo Clinic
NCT04046731
Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00078195
The Leaky Lung Test
University of Rochester
NCT02306473
Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus
Illinois College of Optometry
NCT04418999
Sublingual Cockroach Safety in Adults With Cockroach Allergy & Perennial Allergic Rhinitis With or Without Asthma
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00434421
In Vitro Basophil Responsiveness to Allergen Challenge After Gamma-tocopherol Supplementation in Allergic Asthmatics
University of North Carolina, Chapel Hill
NCT00836368
Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects
Regeneron Pharmaceuticals
NCT01922661
Evaluating for Contact Allergies in Patients With Chronic Urticaria
Tufts Medical Center
NCT00868036
Roflumilast In-Vitro Basophil Release
Creighton University
NCT00613587
Advanced Multimodal Wireless Vital Signs Monitoring for Patients With Asthma and Anaphylaxis
Northwestern University
NCT04360213
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 1 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Allergy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Allergy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Allergy page
16 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Allergy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most Allergy trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Allergy condition card totals 16 registered trials; most-linked intervention Skin Testing; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.